Sanofi

ANZEMET

Manufacturer:

Sanofi

Anzemet HCPCS:

Q0180

HCPCS Code Descriptor:

Dolasetron mesylate, 100 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 24 hour dosage regimen

Category:

Q Code

Anzemet NDCs:

Primary Type:

Oncology-Anti-Emetic

Generic/Specialty Status:

Single-Source

Route of Administration:

Oral

Potential NDC Listing Errors:

Our team did not identify any potential listing errors/discrepancies for the NDCs mapped to this HCPCS code.

About Anzemet:

ANZEMET is an Oncology-Anti-Emetic drug manufactured by Sanofi and administered via the Oral route of administration. The Q Code: Q0180 is aligned to the drug ANZEMET.

ACCESS PRICING AND MORE BY REGISTERING

Q0180 Added Date:

April 1, 1998

Q0180 Effective Date:

April 1, 1998

Q0180 Termination Date:

HCPCS Active

We have not yet identified a manufacturer source of Anzemet billing and coding information.
Our team did not identify a source for Anzemet patient assistance information. Please reach out to our team if you feel that this is a mistake.
ANZEMET prescribing information can be found at the link below:
Information regarding ANZEMET’s side effects can be found at MedlinePlus